Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 158.00K | 866.00K | 1.55M | 2.60M | 5.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.00K | 866.00K | 1.55M | 2.60M | 5.79M |
| Cost of Revenue | 278.81M | 265.46M | 245.07M | 216.68M | 199.01M |
| Gross Profit | -278.65M | -264.60M | -243.53M | -214.08M | -193.22M |
| SG&A Expenses | 47.18M | 44.47M | 43.84M | 42.16M | 41.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 325.99M | 309.93M | 288.91M | 258.84M | 240.54M |
| Operating Income | -325.83M | -309.06M | -287.37M | -256.24M | -234.75M |
| Income Before Tax | -300.55M | -283.65M | -258.76M | -224.53M | -199.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -300.55 | -283.65 | -258.76 | -224.53 | -199.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -300.55M | -283.65M | -258.76M | -224.53M | -199.61M |
| EBIT | -325.83M | -309.06M | -287.37M | -256.24M | -234.75M |
| EBITDA | -322.43M | -305.70M | -283.99M | -252.86M | -231.40M |
| EPS Basic | -4.36 | -4.27 | -3.90 | -3.38 | -3.01 |
| Normalized Basic EPS | -2.72 | -2.67 | -2.43 | -2.11 | -1.88 |
| EPS Diluted | -4.36 | -4.27 | -3.90 | -3.38 | -3.01 |
| Normalized Diluted EPS | -2.72 | -2.67 | -2.43 | -2.11 | -1.88 |
| Average Basic Shares Outstanding | 277.32M | 265.87M | 265.68M | 265.55M | 265.42M |
| Average Diluted Shares Outstanding | 277.32M | 265.87M | 265.68M | 265.55M | 265.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |